Table 1.
Patient | Age/sex | Previous allergic disease | Culprit agents | Symptoms | Anaphylaxisb | Time to onset | Treatment | ED | Time to resolution | Skin test performed | Time from reaction to the skin test | Skin test result | Time between vaccine doses | Vaccine outcomec |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 24F | None | Pfizer-BioNTech vaccine | Urticaria | No | 3 h | Antihistamines | No | 4 d | PEG | 12 d | Negative | 23 d | No reaction |
2 | 54F | Drug allergy | Pfizer-BioNTech vaccine | Tachycardia, rhinorrhea | No | 10 min | None | No | 10 min | PEG, MP acetate | 7 d | Negative | 18 d | No reaction |
3 | 36F | None | Pfizer-BioNTech vaccine | Facial flushing | No | 5 min | Antihistamines | No | 1 h | PEG, MP acetate, TC acetonide | 20 d | Negative | 21 d | No reaction |
4 | 52M | Venom anaphylaxis | Pfizer-BioNTech vaccine | Oral pruritus, throat fullness | No | Immediate | None | No | 5 min | PEG | 10 d | Negative | 21 d | No reaction |
5 | 45F | Food allergy | Pfizer-BioNTech vaccine | Urticaria, throat tightness | No | 8 h | None | No | Unknown | PEG | 20 d | Negative | 29 d | No reaction |
6 | 33F | Asthma, venom anaphylaxis | Pfizer-BioNTech vaccine | Urticaria, tachycardia | No | 15 min | Antihistamines | No | 12-24 h | PEG | 20 d | Negative | 23 d | No reaction |
7 | 20M | Vaccine allergy (flu) | Moderna vaccine | Angioedema | No | 3 h | Steroids, antihistamines | Yes | 24 h | Expandedd | 20 d | Negative | N/A | Not given |
8 | 22F | Allergic rhinitis | Moderna vaccine | Angioedema, wheezing, throat pruritus | Level 1 | 20 min | Antihistamines, steroids | Yes | 6 h | Expandedd | 21 d | Negative | 51 d | Minor lip/tongue tingling |
9 | 69M | Drug allergy | Moviprep (PEG) | Rash, flushing | No | During prep | Antihistamines | No | 1 h | PEG | 2 y | Negative | N/A | No reaction (Pfizer) |
10 | 73F | Asthma, drug allergy | Moviprep (PEG) | Headache, nausea | No | Unknown | Unknown | No | Unknown | PEG | 5 y | Negative | N/A | No reaction (Moderna) |
11 | 46F | Vaccine allergy (flu) | Methylprednisolone acetate (PEG) | Urticaria, dizzy, flushing | No | 15 min | Epinephrine, steroids, antihistamines | No | 12 h | Expandedd | 3 mo | Positive (PEG and MP acetate)e | N/A | Not given |
12 | 74M | Drug allergy | Triamcinolone acetonide (polysorbate 80) | Urticaria, wheezing | Level 1 | 1 h | Steroids, antihistamines | Yes | Unknown | PEG, MP acetate, TC acetonide | 3 y | Negative | N/A | No reaction (Pfizer) |
13 | 55F | Anaphylaxis | Influenza vaccinesf (polysorbate 20/80) | Flushing, wheezing, cough, throat tightness | Level 1 | 20 min | Epinephrine, steroids, antihistamines | Yes | Unknown | PEG, Polysorbate 20 | 7 y | Negative | N/A | No reaction (Pfizer) |
14 | 67F | Food allergy, anaphylaxis | MiraLAX (PEG) | Oral urticaria | No | 2 h | Unknown | No | Unknown | Expandedd | Unknown | Negative | N/A | No reaction (Moderna) |
15 | 60M | Vaccine allergy (Shingrix) | Shingrix (polysorbate 80) | Flushing, urticaria | No | 2 h | Antihistamines, steroids | Yes | 2 d | Expandedd | 3 mo | Negative | N/A | No reaction (Moderna) |
Abbreviations: COVID-19, coronavirus disease 2019; ED, emergency department; F, female; M, male; MP, methylprednisolone; PEG, polyethylene glycol; TC, triamcinolone.
Patients 1 to 8: reaction to first COVID vaccine dose; patients 9 to 15: no previous vaccine dose, reported previous PEG or polysorbate allergy.
Determined by using the Brighton criteria.9
Refers to second vaccine dose in patients 1 to 8 or first vaccine dose in patients 9 to 15. All doses were given with a 30-minute observation period.
Expanded skin testing included PEG, methylprednisolone acetate, methylprednisolone sodium, triamcinolone acetonide, and polysorbate 20.
PEG 1:1 skin prick: 5 × 5 wheal, 10 × 10 flare; methylprednisolone acetate 0.1 mg/mL intradermal: 6 × 6 wheal, 8 × 8 flare (all measurements in mm).
H1N1 vaccines FluBlok and Fluxrix.